60 Degrees Pharmaceuticals’ (SXTP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report report published on Friday morning, MarketBeat.com reports. The firm currently has a $6.00 price objective on the stock.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, October 8th. Ascendiant Capital Markets reduced their price objective on 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating for the company in a research note on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $4.50.

60 Degrees Pharmaceuticals Price Performance

Shares of NASDAQ:SXTP opened at $0.91 on Friday. The company’s fifty day moving average price is $1.41 and its 200 day moving average price is $1.77. 60 Degrees Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $12.45. The firm has a market capitalization of $3.73 million, a P/E ratio of -0.12 and a beta of 2.79.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.55. The company had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.38 million. On average, sell-side analysts anticipate that 60 Degrees Pharmaceuticals will post -5.09 EPS for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.